Multiple Myeloma
Conditions
Keywords
Relapsed/Refractory Multiple Myeloma, carfilzomib, panobinostat
Brief summary
Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis. Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is a pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo with proteasome inhibitors. The combination should enhance the activity of both agents against myeloma cells. In Phase I, the optimal doses of the combination of carfilzomib and panobinostat will be determined. Assuming this combination is feasible, the Phase II portion will proceed using the doses determined in Phase I.
Detailed description
In this open-label, non-randomized Phase I/II study, a maximum of 4 planned dose levels of carfilzomib and panobinostat were evaluated to determine the maximum tolerated dose (MTD) to administer. The MTD was not reached so patients in Phase II received treatment at dose level 4 to further assess efficacy. Response to treatment was evaluated after each 4-week cycle. Those having an objective response or stable disease are continuing treatment until disease progression or unacceptable toxicity occurs. As the MTD in the 4 planned dose levels were not reached, a parallel Phase I study was initiated to examine additional dose levels using a traditional 3+3 design. If these dose levels are tolerable, then more patients will be recruited into an expansion cohort to assess efficacy at the new dose level(s).
Interventions
DRUGpanobinostat
Specified dose on specified days
DRUGcarfilzomib
Specified dose on specified days
Sponsors
Onyx Therapeutics, Inc.
Novartis
SCRI Development Innovations, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Eligible participants must have multiple myeloma using standard criteria. 2. Patients must have measurable disease requiring systemic therapy defined as at least one of the following: * Serum M-protein ≥1 g/dl (≥10 g/l) * Urine M-protein ≥200 mg/24 hrs * Serum free light chain assay: involved free light chain level ≥10 mg/dl (≥100 mg/l) provided the serum free light chain ratio is abnormal 3. Must have progressed during or after at least one previous bortezomib-containing treatment regimen. Patients who have received previous high-dose therapy/autologous stem cell transplantation are eligible. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 5. Must meet the following laboratory criteria: * Absolute neutrophil count (ANC) ≥1000/μL; * Platelets ≥70,000/microL; * AST or ALT and alkaline phosphatase (ALP) must be ≤ 2.5 x ULN, or ≤ 5 x ULN in patients with plasmacytomas of the liver; * Total bilirubin ≤ 1.5 x the institutional ULN; * Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min; * Serum potassium, calcium, magnesium WNL (These may be corrected prior to starting therapy, to make the patient eligible.) 6. Ability to swallow oral medications. 7. Baseline MUGA or ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional limits of normal. 8. Male or females ≥ 18 years of age. 9. Female patients must not be of child-bearing potential or must agree to use adequate contraceptive measures. 10. Male patients willing to use adequate contraceptive measures. 11. Willingness and ability to comply with the trial and follow-up procedures. 12. Ability to understand the nature of this trial and give written informed consent.
Exclusion criteria
1. Currently receiving or have received systemic cancer therapy (chemotherapy, biologic therapy) ≤ 21 days of initiating study therapy. For patients receiving small molecule targeted therapy, study treatment may begin \>21 days after last dose or \>5 half lives of previous treatment, whichever is shorter. Patients must have completed radiation therapy ≥7 days prior to starting study treatment. Patients must have recovered from or come to a new chronic stable baseline from all treatment-related toxicities. Dexamethasone or other high-dose steroid therapy must be stopped ≥ days prior to starting study treatment. 2. Previous treatment with HDAC, DAC, HSP90 or valproic acid for treatment of cancer. 3. Requires valproic acid for any medical condition during the study ≤5 days prior to first panobinostat treatment. 4. Patient has not recovered from all therapy-related toxicities associated with prior treatments to \< Grade 2 CTCAE. 5. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib). 6. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis ≤14 days prior to study entry. 7. Patients using medications that have a risk of prolonging the QT interval or inducing Torsade de Pointes if treatment cannot be discontinued or switched to a different medication prior to receiving study drug. 8. Patients with \> grade 2 diarrhea. 9. Patients with impaired cardiac function. 10. Infection requiring IV antibiotics. 11. Patients with \> grade 2 peripheral neuropathy or with uncontrolled pain. 12. Women who are pregnant or lactating. 13. Any concurrent medical illness that may impair the ability of the patient to tolerate study treatment and comply with the requirements of the study. 14. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study. 15. Use of any non-approved or investigational agent ≤30 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study. 16. Presence of other active cancers, or history of treatment for invasive cancer ≤ 5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 28 days from the start of study treatment | Using a traditional 3+3 dose escalation design, successive cohorts of subjects will receive a fixed dose level of the drug combination. The MTD is defined as the highest dose level at which ≤1 of 6 subjects experiences a dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.0. DLT is defined as any of the following that are determined to be related to study treatment during Cycle 1: Grade 4 neutropenia for \>7 days, Febrile neutropenia, Grade 3 thrombocytopenia with ≥ Grade 2 bleeding, Grade 4 thrombocytopenia \> 7 days, ≥ Grade 2 neuropathy with uncontrolled pain, ≥ Grade 3 non-hematologic drug-related toxicity (excluding alopecia), despite optimal supportive care lasting \>72 hours or requiring a dose reduction in the first cycle and Patients who are unable to receive 75% of the required doses of both agents secondary to toxicity. Number of Participants With such Dose Limiting Toxicities (DLT) at each level are reported here. |
| Phase II: Overall Response Rate | up to 6 years | Defined as the percentage of patients with confirmed complete response, very good partial response, or partial response (CR, VGPR, or PR) according to International Myeloma Working Group Uniform Response Criteria. CR=bone marrow contains ≤5% plasma cells; negative fixation on serum and urine; disappearance of soft tissue plasmacytomas. VGPR=≥90% reduction from baseline serum; urine M-protein level 100mg for 24h. PR=≥50% reduction from baseline in serum M-protein; disappearance of any soft tissue plasmacytomas. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time-to-progression (TTP) | up to 6 years | Measured from date of first treatment until date of first documented progression as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca \>11.5mg/dL) for patients without hypercalcemia at baseline |
| Progression-free-survival (PFS) | up to 6 years | Measured from date of first protocol treatment until date of tumor progression or death as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca \>11.5mg/dL) for patients without hypercalcemia at baseline |
| Overall-survival (OS) | up to 6 years | Measured from time of first study treatment until date of death or date last known alive. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 27 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 27 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 4 |
| Dose Level 2 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 36 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 36 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 3 |
| Dose Level 3 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 3 |
| Dose Level 4 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 3 |
| Dose Level 5 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19 | 3 |
| Dose Level 6 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 3 |
| Expansion Dose Level 4 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 31 |
| Expansion Dose Level 6 Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16
Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
panobinostat: Specified dose on specified days
carfilzomib: Specified dose on specified days | 30 |
| Total | 80 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 10 |
| Overall Study | Conditions requiring other treatment not permitted by protocol | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Overall Study | Disease progression | 3 | 2 | 3 | 1 | 2 | 2 | 14 | 10 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 6 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 2 | 0 | 1 | 6 | 3 |
Baseline characteristics
| Characteristic | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Dose Level 5 | Dose Level 6 | Expansion Dose Level 4 | Expansion Dose Level 6 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 63 years STANDARD_DEVIATION 6.88 | 54 years STANDARD_DEVIATION 13.53 | 70.7 years STANDARD_DEVIATION 6.81 | 56.3 years STANDARD_DEVIATION 9.71 | 71.3 years STANDARD_DEVIATION 8.08 | 67.3 years STANDARD_DEVIATION 13.05 | 65.7 years STANDARD_DEVIATION 10.14 | 65.1 years STANDARD_DEVIATION 11.16 | 65 years STANDARD_DEVIATION 10.56 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 23 Participants | 26 Participants | 68 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 6 Participants | 2 Participants | 8 Participants |
| Pre-treatment ECOG 0 - Asymptomatic | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 1 Participants | 12 Participants | 15 Participants | 38 Participants |
| Pre-treatment ECOG 1 - Symptomatic but completely ambulatory | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 16 Participants | 15 Participants | 39 Participants |
| Pre-treatment ECOG 2 - symptomatic, <50% in bed during the day | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 00 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 5 Participants | 2 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 2 Participants | 2 Participants | 3 Participants | 3 Participants | 2 Participants | 3 Participants | 24 Participants | 27 Participants | 66 Participants |
| Sex: Female, Male Female | 3 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 20 Participants | 12 Participants | 40 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants | 2 Participants | 2 Participants | 3 Participants | 2 Participants | 11 Participants | 18 Participants | 40 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 4 | 0 / 3 | 1 / 3 | 1 / 3 | 2 / 3 | 2 / 3 | 20 / 31 | 12 / 30 |
| other Total, other adverse events | 4 / 4 | 3 / 3 | 3 / 3 | 3 / 3 | 3 / 3 | 3 / 3 | 31 / 31 | 30 / 30 |
| serious Total, serious adverse events | 1 / 4 | 1 / 3 | 0 / 3 | 2 / 3 | 1 / 3 | 0 / 3 | 16 / 31 | 13 / 30 |
Outcome results
Primary
Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage
Using a traditional 3+3 dose escalation design, successive cohorts of subjects will receive a fixed dose level of the drug combination. The MTD is defined as the highest dose level at which ≤1 of 6 subjects experiences a dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.0. DLT is defined as any of the following that are determined to be related to study treatment during Cycle 1: Grade 4 neutropenia for \>7 days, Febrile neutropenia, Grade 3 thrombocytopenia with ≥ Grade 2 bleeding, Grade 4 thrombocytopenia \> 7 days, ≥ Grade 2 neuropathy with uncontrolled pain, ≥ Grade 3 non-hematologic drug-related toxicity (excluding alopecia), despite optimal supportive care lasting \>72 hours or requiring a dose reduction in the first cycle and Patients who are unable to receive 75% of the required doses of both agents secondary to toxicity. Number of Participants With such Dose Limiting Toxicities (DLT) at each level are reported here.
Time frame: 28 days from the start of study treatment
Population: Includes all Phase 1 patients receiving assigned study dosing
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
| Dose Level 2 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
| Dose Level 3 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
| Dose Level 4 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
| Dose Level 5 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
| Dose Level 6 | Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage | 0 Participants |
Primary
Phase II: Overall Response Rate
Defined as the percentage of patients with confirmed complete response, very good partial response, or partial response (CR, VGPR, or PR) according to International Myeloma Working Group Uniform Response Criteria. CR=bone marrow contains ≤5% plasma cells; negative fixation on serum and urine; disappearance of soft tissue plasmacytomas. VGPR=≥90% reduction from baseline serum; urine M-protein level 100mg for 24h. PR=≥50% reduction from baseline in serum M-protein; disappearance of any soft tissue plasmacytomas.
Time frame: up to 6 years
Population: All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 | Phase II: Overall Response Rate | 74 percentage of participants |
| Dose Level 2 | Phase II: Overall Response Rate | 84 percentage of participants |
Secondary
Overall-survival (OS)
Measured from time of first study treatment until date of death or date last known alive.
Time frame: up to 6 years
Population: All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Overall-survival (OS) | 29.2 months |
| Dose Level 2 | Overall-survival (OS) | 44.6 months |
Secondary
Progression-free-survival (PFS)
Measured from date of first protocol treatment until date of tumor progression or death as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca \>11.5mg/dL) for patients without hypercalcemia at baseline
Time frame: up to 6 years
Population: All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Progression-free-survival (PFS) | 12.1 months |
| Dose Level 2 | Progression-free-survival (PFS) | 10.3 months |
Secondary
Time-to-progression (TTP)
Measured from date of first treatment until date of first documented progression as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca \>11.5mg/dL) for patients without hypercalcemia at baseline
Time frame: up to 6 years
Population: All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Time-to-progression (TTP) | 11.6 months |
| Dose Level 2 | Time-to-progression (TTP) | 11.7 months |